Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: A different pathophysiological approach

被引:24
作者
Jaeger, BR
Goehring, P
Schirmer, J
Uhrig, S
Lohse, P
Kreuzer, E
Reichart, B
Seidel, D
机构
[1] Univ Munich, Univ Hosp Grosshadern, Inst Clin Chem, D-81377 Munich, Germany
[2] Univ Munich, Univ Hosp Grosshadern, Dept Cardiac Surg, D-81377 Munich, Germany
来源
THERAPEUTIC APHERESIS | 2001年 / 5卷 / 04期
关键词
atherosclerosis; cardiovascular diseases; cholesterol; coagulation; fibrinogen; low-density lipoprotein apheresis; thrombolysis;
D O I
10.1046/j.1526-0968.2001.00350.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypercoagulability is a key contributor to acute cardiovascular syndromes and to various microcirculatory disorders. The use of heparin-mediated extracorporeal low-density lipoprotein/fibrinogen precipitation (HELP) apheresis makes a controlled, immediately effective reduction of clotting factors possible, and induces subsequent positive effects on plasma viscosity, erythrocyte aggregation, and microcirculation. Oxygen supply to an ischemic artery can thus be increased without hemodilution, qualifying the HELP system as a possible therapeutic tool in the treatment of acute cardiovascular syndromes and microcirculatory disorders.
引用
收藏
页码:252 / 259
页数:8
相关论文
共 38 条
[11]  
Jaeger B R, 1999, Ther Apher, V3, P214, DOI 10.1046/j.1526-0968.1999.00156.x
[12]  
Jaeger BR, 1999, ACT NEUR S, V73, P81
[13]  
Jaeger BR, 1997, CIRCULATION, V96, P154
[14]   Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system [J].
Julius, U ;
Siegert, G ;
Gromeier, S .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2000, 23 (03) :199-206
[15]  
KELLEHER CC, 1972, EUR J EPIDEMIOL S1, V8, P79
[16]   THE POSSIBLE ROLE OF HEMORHEOLOGY IN ATHEROTHROMBOGENESIS [J].
KOENIG, W ;
ERNST, E .
ATHEROSCLEROSIS, 1992, 94 (2-3) :93-107
[17]   Sol Sherry Lecture in thrombosis - Research on clot stabilization provides clues for improving thrombolytic therapies [J].
Lorand, L .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (01) :2-9
[18]  
MEADE T W, 1987, Blood Reviews, V1, P2, DOI 10.1016/0268-960X(87)90013-0
[19]   THE EFFECT OF PHYSIOLOGICAL LEVELS OF FIBRINOGEN ON PLATELET-AGGREGATION [J].
MEADE, TW ;
VICKERS, MV ;
THOMPSON, SG ;
SEGHATCHIAN, MJ .
THROMBOSIS RESEARCH, 1985, 38 (05) :527-534
[20]   FIBRINOLYTIC-ACTIVITY, CLOTTING FACTORS, AND LONG-TERM INCIDENCE OF ISCHEMIC-HEART-DISEASE IN THE NORTHWICK-PARK-HEART-STUDY [J].
MEADE, TW ;
RUDDOCK, V ;
STIRLING, Y ;
CHAKRABARTI, R ;
MILLER, GJ .
LANCET, 1993, 342 (8879) :1076-1079